This is your brain on ChatGPT
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Sizzle. Sizzle. That's the sound of your neurons frying over the heat of a thousand GPUs as your generative AI tool of choice cheerfully churns through your workload. As it turns out, offloading all of that cognitive effort to a robot as you look on in luxury is turning your brain into a couch potato.
That's what a recently published (and yet to be peer-reviewed) paper from some of MIT's brightest minds suggests, anyway.
The study examines the "neural and behavioral consequences" of using LLMs (Large Language Models) like ChatGPT for, in this instance, essay writing. The findings raise serious questions about how long-term use of AI might affect learning, thinking, and memory. More worryingly, we recently witnessed it play out in real life.
The study, titled: Your Brain on ChatGPT: Accumulation of Cognitive Debt when Using an AI Assistant for Essay Writing Task, involved 54 participants split into three groups:
LLM group: Instructed to complete assignments using only ChatGPT, and no other websites or tools.
Search engine group: Allowed to use any website except LLMs, even AI-enhanced answers were forbidden.
Brain-only group: Relying only on their own knowledge.
Across three sessions, these groups were tasked with writing an essay about one of three changing topics. An example of the essay question for the topic of "Art" was: "Do works of art have the power to change people's lives?"
Participants then had 20 minutes to answer the question related to their chosen topic in essay form, all while wearing an Enobio headset to collect EEG signals from their brain.
In a fourth session, LLM and Brain-only groups were swapped to measure any potential lasting impact of prior sessions.
The results? Across the first three tests, Brain-only writers had the most active, widespread brain engagement during the task, while LLM-assisted writers showed the lowest levels of brain activity across the board (although routinely completed the task fastest). Search engine-assisted users generally fell somewhere in between the two.
In short, Brain-only writers were actively engaging with the assignment, producing more creative and unique writing while actually learning. They were able to quote their essays afterwards and felt strong ownership of their work.
Alternatively, LLM users engaged less over each session, began to uncritically rely on ChatGPT more as the study went on, and felt less ownership of the results. Their work was judged to be less unique, and participants often failed to accurately quote from their own work, suggesting reduced long-term memory formation.
Researchers referred to this phenomenon as "metacognitive laziness" — not just a great name for a Prog-Rock band, but also a perfect label for the hazy distance between autopilot and Copilot, where participants disengage and let the AI do the thinking for them.
But it was the fourth session that yielded the most worrying results. According to the study, when the LLM and Brain-only group traded places, the group that previously relied on AI failed to bounce back to pre-LLM levels tested before the study.
To put it simply, sustained use of AI tools like ChatGPT to "help" with tasks that require critical thinking, creativity, and cognitive engagement may erode our natural ability to access those processes in the future.
But we didn't need a 206-page study to tell us that.
On June 10, an outage lasting over 10 hours saw ChatGPT users cut off from their AI assistant, and it provoked a disturbing trend of people openly admitting, sans any hint of awareness, that without access to OpenAI's chatbot, they'd suddenly forgotten how to work, write, or function.
This study may have used EEG caps and grading algorithms to prove it, but most of us may already be living its findings.
When faced with an easy or hard path, many of us would assume that only a particularly smooth-brained individual would willingly take the more difficult, obtuse route.
However, as this study claims, the so-called easy path may be quietly sanding down our frontal lobes in a lasting manner — at least when it comes to our use of AI.
That's especially frightening when you think of students, who are adopting these tools en masse, with OpenAI itself pushing for wider embrace of ChatGPT in education as part of its mission to build "an AI-Ready Workforce."
A 2023 study conducted by Intelligent.com revealed that a third of U.S. college students surveyed used ChatGPT for schoolwork during the 2022/23 academic year.
In 2024, a survey from the Digital Education Council claimed that 86% of students across 16 countries use artificial intelligence in their studies to some degree.
AI's big sell is productivity, the promise that we can get more done, faster. And yes, MIT researchers have previously concluded that AI tools can boost worker productivity by up to 15%, but the long-term impact suggests codependency over competency. And that sounds a lot like regression.
At least for the one in front of the computer.
Sizzle. Sizzle.
Is Microsoft misleading users about Copilot? New claims point the finger at AI productivity
Why OpenAI engineers are turning down $100 million from Meta, according to Sam Altman
Google's latest Gemini 2.5 models are its biggest response to ChatGPT yet — and they're already live

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes
Common obesity drug reduced the risk of disease progression by 54% CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including improvement in symptoms, quality of life, and disease progression in patients. An analysis of the STRIDE trial was presented as a late-breaking symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and simultaneously published in Diabetes Care®. PAD is a serious condition impacting 230 million individuals globally and up to 30% of people with diabetes. PAD narrows arteries and reduces blood flow to the legs, causing marked disability, affecting quality of life, and putting people at increased risk of severe complications including amputations and death. Treatment options are currently limited, and little advancements in PAD treatment have occurred for more than 25 years. The STRIDE trial is a phase 3, multinational, double-blind, randomized clinical trial conducted at 112 outpatient clinical trial sites in 20 countries in North America, Asia, and Europe. 792 patients aged 18 years and older with type 2 diabetes and PAD with intermittent claudication (a symptom of PAD that causes muscle pain or cramping in the legs during physical activity) and reduced ankle-brachial or toe-brachial index (indicators of restricted blood flow to the legs), were randomly assigned to receive either semaglutide (n=396) or placebo (n=396) over a 52-week period to assess the impact on walking capacity, symptoms, and quality of life. The median age was 68 years, and 195 (25%) participants were female and 597 (75%) were male. The sub-analysis builds on results previously published in The Lancet, demonstrating that semaglutide significantly improved walking outcomes in people with PAD and diabetes, enhanced quality of life, and reduced the risk of disease progression by 54%. At week 52, the estimated median ratio to baseline in maximum walking distance was 1.21 in the semaglutide group compared to 1.08 in the placebo group. Semaglutide was well tolerated, with no treatment-related deaths and a low rate of serious adverse events (1%), consistent with its known safety profile. The analyses from STRIDE presented new and critical information on the benefits of semaglutide, which were observed independent of baseline levels of A1C, duration of diabetes, or intensity of diabetes. Furthermore, the benefits were seen across all BMI categories and regardless of the treatment with SGLT2 inhibitors. "These findings indicate that clinicians can now recognize semaglutide as a vascular protective medication, with benefits that extend beyond lowering weight or A1C," said Professor Subodh Verma, MD, PhD, FRCSC, FAHA, FCAHS, cardiovascular surgeon, University of Toronto, Toronto, Canada, and senior author of the STRIDE trial. "The totality of data now suggest that in people with diabetes, semaglutide favorably affects the pipes [atherosclerosis], pump [heart failure], filter [kidney outcomes]. And, in patients with PAD, these new data provide robust evidence that semaglutide is a therapy to improve their function, quality of life, and progression of disease."The study authors indicate that further research is warranted to understand whether these benefits extend to individuals with PAD who do not have diabetes. Research presentation details:Dr. Verma will present the findings at the following symposium: Symposium: Diabetes and Peripheral Artery Disease—Evolving Role of GLP-1 RA and New Insights from the STRIDE Trial Presented on Saturday, June 21 at 1:30 p.m. CT About the ADA's Scientific SessionsThe ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions. About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn). Media Contact: Mimi Carmody, MCarmody@ View original content to download multimedia: SOURCE American Diabetes Association Sign in to access your portfolio

Associated Press
17 minutes ago
- Associated Press
SpecFive Unveils Voyager: A Solar-Powered, Vehicle-Mounted Meshtastic Node for Reliable Off-Grid Communications
'We've integrated a high-sensitivity GNSS module and an SX1262 LoRa radio in a low-profile package that stays bolted to your vehicle via magnets.'— Daniel Susca, VP Engineering at SpecFive. AUSTIN, TX, UNITED STATES, June 22, 2025 / / -- SpecFive today announced the launch of the Voyager, a rugged, magnetic roof-mounted Meshtastic node engineered to keep teams connected where traditional networks cannot reach. Designed for rapid deployment on any vehicle, the Voyager runs entirely on solar power and requires zero user intervention once mounted, making it ideal for public safety, utility operations, and remote expeditions. 'Maintaining seamless, off-grid communication can mean the difference between mission success and failure,' said Amir Husain, Chairman of SpecFive. 'With the Voyager, we're delivering the perfect vehicle-mounted solution that travels with you and extends your mesh network up to five miles in rural conditions, without the need for cables, charging stations, or complex setup. It's plug-and-play' Key Product Details -LoRa Radio & Mesh Compatibility -SX1262 915 MHz transceiver, ultra low power -Urban range: 1 to 3 miles; rural range: 3 to 5 miles -Fully Meshtastic compatible firmware; Bluetooth LE for messages, locations, or adding more users -Precision GNSS Tracking -Multi-constellation support (GPS, GLONASS, QZSS, BeiDou) -Rapid satellite acquisition even in obstructed or moving environments -Autonomous Solar Power System -6 W monocrystalline solar panel optimized for low-light harvesting -3300 mAh LiPo battery: up to 2 days active operation or 5 days standby without sunlight -Smart power management maximizes uptime and minimizes maintenance -Rugged, Road-Ready Design -Weatherproof ASA enclosure with aerodynamic contours -Rubber-coated neodymium magnets for scratch-safe mounting on any metal surface; no tools required -Standard SMA connector for optional external antennas Physical Specifications -Dimensions: 360 mm × 180 mm × 20 mm -Weight: 600 g -Case material: ASA -MSRP: $229.99; Intro price: $219.99 'I'm proud of how the Voyager balances power efficiency and durability,' explained Daniel Susca, VP Engineering at SpecFive. 'We've integrated a high-sensitivity GNSS module and an SX1262 LoRa radio in a low-profile package that stays bolted to your vehicle via magnets. Even after days without sun, the battery backup keeps the node online so data packets keep relaying without interruption.' Applications & Target Users 1. Public safety and first responders operating across rugged terrain 2. Utilities and field-service crews in off-grid or hard-to-reach areas 3. Outdoor enthusiasts, overlanders, and search & rescue teams 4. Scientific and environmental researchers in remote locations Availability & Pricing The Voyager is available immediately through SpecFive's online store and authorized distributors at an introductory price of $219.99 per unit. Optional accessories, including high-gain external antennas and vehicle-specific mounting brackets, will be offered starting Q3 2025. Volume pricing and turnkey deployment packages are available upon request. About SpecFive SpecFive designs and manufactures rugged, subscription-free communication solutions for off-grid and remote environments. Leveraging Meshtastic LoRa mesh protocols and purpose-built hardware, SpecFive empowers public safety agencies, industrial operators, and outdoor teams to stay connected without reliance on cellular towers or satellite subscriptions. Niesha Waggonner Specfive +1 512-663-0688 email us here Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Associated Press
17 minutes ago
- Associated Press
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for obesity and key comorbidities EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that it will present new preclinical data supporting apelin receptor (APJ) agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction (HFpEF). The data will be presented at the American Diabetes Association's 85th Scientific Sessions, held June 20–23, 2025, in Chicago, Illinois. 'Our preclinical data demonstrated that APJ activation can confer multiple benefits in models of diabetic obesity and heart failure, and enhance the effects of incretin therapy,' said Kristen Fortney, PhD, CEO and co‑founder of BioAge. 'We are advancing next‑generation APJ agonists to translate this promising biology into new therapies for obesity and its major comorbidities.' APJ is the receptor for apelin, an exercise-induced signaling molecule known as an exerkine. Apelin has been shown in preclinical studies to have the potential to recapitulate many of the downstream benefits of exercise. BioAge's discovery platform identified apelin signaling as a therapeutic target based on analysis of human aging cohorts, which revealed that higher levels of circulating apelin are predictive of improved physical function and increased longevity. BioAge has shown that in preclinical obesity models, APJ agonism can approximately double the weight loss induced by GLP-1 receptor agonists while restoring body composition and muscle function, suggesting that APJ agonists could serve as pharmacological exercise mimetics to enhance incretin therapy. BioAge is advancing multiple APJ agonist approaches, including both oral small-molecule and long-acting injectable formulations, with an IND filing targeted for 2026 [ link ]. In their two presentations, BioAge CMO and EVP Research Paul Rubin, MD, and scientist Shijun Yan, PhD, MBA, will present data that demonstrated that in preclinical models of diabetic obesity and HFpEF, APJ agonist treatment had potential as monotherapy that could be enhanced in combination with incretin therapies. Oral presentation: Saturday Jun 21, 2025 5:00 PM - 5:15 PM CDT Title: An Oral Apelin Receptor Agonist Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with Tirzepatide Session: Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies—Take 1; W181 A-C Presenter: Paul Rubin, MD, Chief Medical Officer and EVP-Research Poster presentation: Sunday Jun 22, 2025 12:30 PM - 1:30 PM CDT Title: The Apelin Receptor Agonist Azelaprag Shows Cardioprotective Effects as Monotherapy and Enhanced Benefits with Semaglutide in a Diet-Induced Obesity Model of Heart Failure with Preserved Ejection Fraction Session: Poster Hall F1, Board No. 866 Presenter: Shijun Yan, PhD, MBA, Senior Scientist, In Vivo Biology The visual materials for the presentations will be made available on the BioAge investor website concurrent with the beginning of their respective sessions. About BioAge Labs, Inc. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. IND submission and initiation of a Phase 1 SAD/MAD trial are planned for mid-2025, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge's additional preclinical programs, which leverage insights from the Company's proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging. Forward-looking statements This press release contains 'forward-looking statements' within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, including BGE-102 and our APJ program, the timing and results of our planned clinical trials, risks associated with clinical trials, including our ability to adequately manage clinical activities, the timing of our IND filing for BGE-102 or our APJ program, our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates or their ultimate ability to treat human disease, the expected timeline for completing proteomic analysis, anticipated analytical results and the potential for identifying novel therapeutic targets, and general economic, industry and market conditions. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'possible,' 'will,' 'would,' and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to the imposition of tariffs and other trade barriers; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading 'Risk Factors' included in BioAge's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on May 6, 2025, and BioAge's other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Contacts PR: Chris Patil, [email protected] IR: Dov Goldstein, [email protected] Partnering: [email protected] Web: